Open Nav

Please submit your session questions in advance at http://bit.ly/BIOCEO19question

Propanc Biopharma Inc.

Propanc Biopharma is a biopharmaceutical company developing new cancer treatments for solid tumors. The company has developed a formulation of anti-cancer compounds designed to control or prevent tumors from recurring and spreading throughout the body by using proenzymes, which are inactive precursors of enzymes.

  • Date:Tuesday, February 12
  • Time:9:45 AM - 10:00 AM
  • Room:Hudson/Empire
  • Location:7th Floor
  • Session Type:Company Presentation
  • Please submit your session questions in advance at:http://bit.ly/BIOCEO19question
  • Company Presentation - Presentation Type:Publicly Traded Company
  • Submission ID:23328
  • Goal for Presentation:To inform life sciences investors regarding the exciting potential of our breakthrough technology.
  • Company Website:www.propanc.com
  • Company HQ City:Camberwell
  • Company HQ Country:Australia
  • Market Cap:$5.86 million
  • Ticker:PPCB
  • Exchange:OTCQB
  • CEO/Top Company Official:James Nathanielsz
  • Year Founded:2007
  • Main Therapeutic Focus:Oncology
  • Lead Product in Development:PRP (trypsinogen/chymotrypsinogen I.V injection)
  • Development Phase of Primary Product:Pre-Clinical
  • Number Of Unlicensed Products (For Which You Are Seeking Partners):1
  • Additional Information/Comments:Our lead product, PRP, is a solution for intravenous administration of a combination of two pancreatic proenzymes, trypsinogen and chymotrypsinogen. PRP prevents tumor recurrence and metastasis from solid tumors. PRP's unique patented approach is designed to target and eradicate cancer stem cells that are not killed by standard treatments. We recently completed preclinical development and are currently undertaking IMP manufacture to commence first-in-human studies in 2019. PRP received Orphan Drug Designation Status from the FDA for the treatment of pancreatic cancer. The company has joint research partnerships with Granada and Jaen Universities, as well as University Hospital in Granada, Spain, known as the Public Health Foundation Network, or FIBAO. The company has raised approx. $18 million and recently entered into a $10 million financing facility with an accredited institutional investor to fund future clinical development activities for our lead product, PRP.
Speakers
James Nathanielsz
Propanc Biopharma Inc.
Back